CR10879A - CYCLIZED DERIVATIVES AS EG-5 INHIBITORS - Google Patents

CYCLIZED DERIVATIVES AS EG-5 INHIBITORS

Info

Publication number
CR10879A
CR10879A CR10879A CR10879A CR10879A CR 10879 A CR10879 A CR 10879A CR 10879 A CR10879 A CR 10879A CR 10879 A CR10879 A CR 10879A CR 10879 A CR10879 A CR 10879A
Authority
CR
Costa Rica
Prior art keywords
inhibitors
cyclized derivatives
cyclized
derivatives
Prior art date
Application number
CR10879A
Other languages
Spanish (es)
Inventor
Rustum Boyce
Eric Martin
Weibo Wang
Hong Yang
Paul A Barsanti
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of CR10879A publication Critical patent/CR10879A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles
    • A61K31/422—Oxazoles not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Engineering & Computer Science (AREA)
  • Hematology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Emulsifying, Dispersing, Foam-Producing Or Wetting Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
CR10879A 2007-01-05 2009-06-19 CYCLIZED DERIVATIVES AS EG-5 INHIBITORS CR10879A (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US88374007P 2007-01-05 2007-01-05

Publications (1)

Publication Number Publication Date
CR10879A true CR10879A (en) 2009-08-05

Family

ID=39577804

Family Applications (1)

Application Number Title Priority Date Filing Date
CR10879A CR10879A (en) 2007-01-05 2009-06-19 CYCLIZED DERIVATIVES AS EG-5 INHIBITORS

Country Status (30)

Country Link
US (3) US7820646B2 (en)
EP (1) EP2106399A2 (en)
JP (1) JP2010515687A (en)
KR (1) KR20090097210A (en)
CN (1) CN101622247A (en)
AR (1) AR064760A1 (en)
AU (1) AU2008205169B2 (en)
BR (1) BRPI0806264A2 (en)
CA (1) CA2674318A1 (en)
CL (1) CL2008000029A1 (en)
CO (1) CO6561828A2 (en)
CR (1) CR10879A (en)
DO (1) DOP2009000169A (en)
EA (1) EA200900924A1 (en)
EC (1) ECSP099485A (en)
GE (1) GEP20125415B (en)
GT (1) GT200900192A (en)
HN (1) HN2009001262A (en)
MA (1) MA31080B1 (en)
MX (1) MX2009007260A (en)
NI (1) NI200900134A (en)
NZ (1) NZ577727A (en)
PE (1) PE20081850A1 (en)
SM (1) SMP200900065B (en)
SV (1) SV2009003325A (en)
TN (1) TN2009000287A1 (en)
TW (1) TW200836722A (en)
UA (1) UA97821C2 (en)
WO (1) WO2008086122A2 (en)
ZA (1) ZA200904175B (en)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8252832B2 (en) 2007-12-14 2012-08-28 Novartis Ag Kinesin inhibitors as cancer therapeutics
US8748626B2 (en) * 2010-04-15 2014-06-10 Novartis Ag Oxazole and thiazole compounds as KSP inhibitors
US8546434B2 (en) 2010-04-15 2013-10-01 Novartis Ag Triazole compounds as KSP inhibitors
EP2390247A1 (en) 2010-05-26 2011-11-30 Netherlands Organisation for Scientific Research (Advanced Chemical Technologies for Sustainability) Preparation of caprolactone, caprolactam, 2,5-tetrahydrofuran dimethanol, 1,6-hexanediol or 1,2,6-hexanetriol from 5-hydroxymethyl-2-furfuraldehyde
GB201113538D0 (en) 2011-08-04 2011-09-21 Karobio Ab Novel estrogen receptor ligands
WO2014151030A1 (en) * 2013-03-15 2014-09-25 Novartis Ag Cell proliferation inhibitors and conjugates thereof
US9498540B2 (en) 2013-03-15 2016-11-22 Novartis Ag Cell proliferation inhibitors and conjugates thereof
CA2934617A1 (en) * 2013-12-23 2015-07-02 Bayer Pharma Aktiengesellschaft Antibody drug conjugates (adcs) with kinesin spindle protein (ksp)
AU2016282723B2 (en) 2015-06-22 2021-09-23 Bayer Pharma Aktiengesellschaft Antibody drug conjugates (ADCs) and antibody prodrug conjugates (APDCs) with enzymatically cleavable groups
CN105330657B (en) * 2015-12-08 2019-05-21 华润双鹤药业股份有限公司 The preparation method of the chloro- 2- of 5- [5- (R)-methyl-1,4- Diazesuberane -1-] benzoxazoles
CN105367506B (en) * 2015-12-08 2021-02-05 华润双鹤药业股份有限公司 Preparation method of chiral high piperazine ring
WO2017216028A1 (en) 2016-06-15 2017-12-21 Bayer Pharma Aktiengesellschaft Specific antibody-drug-conjugates (adcs) with ksp inhibitors and anti-cd123-antibodies
WO2018114804A1 (en) 2016-12-21 2018-06-28 Bayer Pharma Aktiengesellschaft Specific antibody drug conjugates (adcs) having ksp inhibitors
KR102556826B1 (en) 2016-12-21 2023-07-18 바이엘 파마 악티엔게젤샤프트 Antibody drug conjugates (ADCs) with enzymatically cleavable groups
KR20210033470A (en) 2018-06-18 2021-03-26 바이엘 악티엔게젤샤프트 Enzymatically cleavable linker and binding agent-drug conjugates directed against CXCR5 with improved activity profile
CN119859151A (en) * 2023-10-19 2025-04-22 北京振东光明药物研究院有限公司 Alkaloid compound separated from rhizoma smilacis glabrae and preparation method and application thereof

Family Cites Families (75)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2550959C3 (en) * 1975-11-13 1980-12-04 Hoechst Ag, 6000 Frankfurt Tetrazolyl-imidazoles and tetrazolyl-benzimidazoles, processes for their preparation and pharmaceuticals containing them
US4235871A (en) * 1978-02-24 1980-11-25 Papahadjopoulos Demetrios P Method of encapsulating biologically active materials in lipid vesicles
US4501728A (en) * 1983-01-06 1985-02-26 Technology Unlimited, Inc. Masking of liposomes from RES recognition
GB2157285B (en) 1984-04-11 1987-10-28 Erba Farmitalia 1h, 7h-pyrazolo1, 5-a pyrimidine-7-one derivatives and process for their preparation
US5023252A (en) * 1985-12-04 1991-06-11 Conrex Pharmaceutical Corporation Transdermal and trans-membrane delivery of drugs
US4837028A (en) * 1986-12-24 1989-06-06 Liposome Technology, Inc. Liposomes with enhanced circulation time
US5011472A (en) * 1988-09-06 1991-04-30 Brown University Research Foundation Implantable delivery system for biological factors
US5859012A (en) * 1996-04-03 1999-01-12 Merck & Co., Inc. Inhibitors of farnesyl-protein transferase
WO1998027108A2 (en) 1996-12-16 1998-06-25 Fujisawa Pharmaceutical Co., Ltd. New amide compounds and their use as nitric oxide synthase inhibitors
US6117940A (en) 1997-10-17 2000-09-12 Mjalli; Adnan M. M. Amino-ketone solid support templates
US6172087B1 (en) * 1998-06-03 2001-01-09 Gpi Nil Holding, Inc. N-oxide of heterocyclic ester, amide, thioester, or ketone hair growth compositions and uses
US6271241B1 (en) * 1999-04-02 2001-08-07 Neurogen Corporation Cycloalkyl and aryl fused aminoalkyl-imidazole derivatives: modulators and GLP-1 receptors
JP2002541146A (en) 1999-04-02 2002-12-03 ニューロゲン コーポレイション Aminoalkyl-imidazole derivatives of aryl and heteroaryl fusions and their use as diabetic agents
TWI283577B (en) 1999-10-11 2007-07-11 Sod Conseils Rech Applic Pharmaceutical composition of imidazole derivatives acting as modulators of sodium channels and the use thereof
US20040132788A1 (en) * 1999-10-11 2004-07-08 Chabrier De Lassauniere Pierre-Etienne Derivatives of heterocycles with 5 members, their preparation and their use as medicaments
US7291641B2 (en) * 1999-10-11 2007-11-06 Societe De Conseils De Recherches Et D'applications Scientifiques (S.C.R.A.S.) Derivatives of heterocycles with 5 members, their preparation and their use as medicaments
ES2263501T3 (en) 1999-10-27 2006-12-16 Cytokinetics, Inc. PROCEDURE AND COMPOSITIONS THAT USE QUINAZOLINONES.
US6545004B1 (en) 1999-10-27 2003-04-08 Cytokinetics, Inc. Methods and compositions utilizing quinazolinones
US6620882B1 (en) 2000-05-02 2003-09-16 Advanced Syntech, Llc Solid support template for preparation of highly functionalized heterocycle compounds
AU2001264872A1 (en) 2000-06-05 2001-12-17 Ortho-Mcneil Pharmaceutical, Inc. Method for synthesis of substituted azole libraries
US6683191B2 (en) 2000-06-05 2004-01-27 Ortho-Mcneil Pharmaceuticals, Inc. Method for synthesis of substituted azole libraries
AU7909801A (en) 2000-08-01 2002-02-13 Sod Conseils Rech Applic Imidazolyl derivatives
CA2425185A1 (en) 2000-10-06 2002-04-11 Stephane De Lombaert Benzimidazole and indole derivatives as crf receptor modulators
WO2002046168A1 (en) 2000-12-07 2002-06-13 Astrazeneca Ab Therapeutic benzimidazole compounds
NZ526622A (en) 2000-12-11 2006-07-28 Amgen Sf Llc CXCR3 antagonists
US6992082B2 (en) 2001-01-19 2006-01-31 Cytokinetics, Inc. Phenothiazine kinesin inhibitors
US20040132830A1 (en) 2001-01-19 2004-07-08 Finer Jeffrey T Triphenylmethane kinesin inhibitors
AU2002363429B2 (en) 2001-11-07 2008-05-08 Merck & Co., Inc. Mitotic kinesin inhibitors
WO2003043995A1 (en) 2001-11-20 2003-05-30 Cytokinetics, Inc. Process for the racemization of chiral quinazolinones
AU2002363960B2 (en) 2001-12-06 2008-07-10 Merck Sharp & Dohme Corp. Mitotic kinesin inhibitors
WO2003049679A2 (en) 2001-12-06 2003-06-19 Merck & Co., Inc. Mitotic kinesin inhibitors
US7378411B2 (en) 2001-12-06 2008-05-27 Merck & Co., Inc. Substituted thienopyrimidinones as a mitotic kinesin inhibitor
ATE424388T1 (en) 2001-12-06 2009-03-15 Merck & Co Inc MITOTIC KINESIN INHIBITORS
CA2467726A1 (en) 2001-12-06 2003-06-19 Merck & Co., Inc. Mitotic kinesin inhibitors
WO2003059289A2 (en) 2002-01-10 2003-07-24 Neurogen Corporation Melanin concentrating hormone receptor ligands: substituted benzoimidazole analogues
AU2003213092A1 (en) 2002-02-15 2003-09-09 Smithkline Beecham Corporation Syntheses of quinazolinones
AU2003249597B2 (en) 2002-03-08 2007-06-28 Merck Sharp & Dohme Corp. Mitotic kinesin inhibitors
US7026312B2 (en) * 2002-03-14 2006-04-11 Boehringer Ingelheim Pharma Gmbh & Co. Kg Substituted piperidines, pharmaceutical compositions containing these compounds, their use and processes for the preparation thereof
DE10211770A1 (en) 2002-03-14 2003-10-02 Boehringer Ingelheim Pharma Novel substituted piperidines, pharmaceutical compositions containing them and processes for their preparation
DE60333094D1 (en) 2002-04-17 2010-08-05 Cytokinetics Inc COMPOUNDS, COMPOSITIONS AND METHODS
GB0209995D0 (en) 2002-05-01 2002-06-12 Merck Sharp & Dohme Therapeutic agents
AU2003245259A1 (en) 2002-05-02 2003-11-17 Neurogen Corporation Substituted imidazole derivatives: gabaa receptor ligands
AU2003301864A1 (en) 2002-05-08 2004-06-07 Neurogen Corporation Substituted imidazolylmethyl pyridine and pyrazine derivatives and their use as gabaa receptor ligands
EP1503993A4 (en) 2002-05-09 2006-05-03 Cytokinetics Inc Compounds, methods and compositions
JP2005530785A (en) 2002-05-09 2005-10-13 サイトキネティクス・インコーポレーテッド Compounds, compositions and methods
AU2003290507A1 (en) 2002-05-10 2004-04-08 Cytokinetics, Inc. Compounds, compositions and methods
WO2003097643A1 (en) 2002-05-17 2003-11-27 Neurogen Corporation Substituted ring-fused imidazole derivates: gabaa receptor ligands
AU2003231799A1 (en) * 2002-05-23 2003-12-12 Merck & Co., Inc. Mitotic kinesin inhibitors
EP1513820A4 (en) 2002-05-23 2006-09-13 Cytokinetics Inc Compounds, compositions, and methods
EP1515949B1 (en) 2002-06-14 2007-03-14 Merck & Co., Inc. Mitotic kinesin inhibitors
KR20050010515A (en) 2002-06-14 2005-01-27 머크 앤드 캄파니 인코포레이티드 Mitotic kinesin inhibitors
EP1556357A4 (en) 2002-06-14 2006-09-13 Cytokinetics Inc Compounds, compositions, and methods
EP1551962A4 (en) 2002-07-08 2007-08-01 Merck & Co Inc BINDING SITE OF MITOTIC KINESIN
EP1539727B1 (en) 2002-07-17 2009-02-18 Cytokinetics, Inc. Compounds, compositions, and methods for treating cellular proliferative diseases
US7211580B2 (en) 2002-07-23 2007-05-01 Cytokinetics, Incorporated Compounds, compositions, and methods
AU2003262747A1 (en) 2002-08-21 2004-03-11 Cytokinetics, Inc. Compounds, compositions, and methods
JP2005539062A (en) 2002-09-13 2005-12-22 サイトキネティクス・インコーポレーテッド Compounds, compositions and methods
CN100579579C (en) 2002-10-01 2010-01-13 诺华疫苗和诊断公司 Anti-cancer and anti-infectious disease compositions and methods of use thereof
DE60307499T2 (en) 2002-11-08 2007-02-01 Neurogen Corp., Branford 4-IMIDAZOLE-1-YLMETHYLPYRIMIDIN DERIVATIVES AS LIGANDS FOR GABAA RECEPTORS
EP1581520A4 (en) * 2002-12-13 2006-08-23 Smithkline Beecham Corp Compounds, compositions and methods
JP2006515886A (en) 2003-01-17 2006-06-08 サイトキネティクス・インコーポレーテッド Compounds, compositions and methods
WO2004071448A2 (en) 2003-02-12 2004-08-26 Transtech Pharma Inc. Substituted azole derivatives as inhibitors of protein tyrosine phosphatases
EP1620092A4 (en) 2003-05-07 2008-04-16 Cytokinetics Inc Compounds, compositions, and methods
EP1622878A4 (en) 2003-05-15 2008-04-09 Cytokinetics Inc Compounds, compositions and methods
EP1636225B1 (en) 2003-06-20 2010-02-24 Novartis Vaccines and Diagnostics, Inc. Pyridino 1,2-a pyrimidin-4-one compounds as anticancer agents
WO2005041888A2 (en) * 2003-11-03 2005-05-12 Cytokinetics, Inc. Pyrimidin-4-one compounds, compositions and methods
US20050187277A1 (en) * 2004-02-12 2005-08-25 Mjalli Adnan M. Substituted azole derivatives, compositions, and methods of use
PT1732926E (en) * 2004-04-06 2009-04-03 Novartis Vaccines & Diagnostic Mitotic kinesin inhibitors
US20080132549A1 (en) 2004-04-14 2008-06-05 Pfizer Inc. Sulphur-Linked Imidazone Compounds for the Treatment of Hiv/Aids
US7618981B2 (en) 2004-05-06 2009-11-17 Cytokinetics, Inc. Imidazopyridinyl-benzamide anti-cancer agents
JP2008502721A (en) * 2004-05-21 2008-01-31 ノバルティス ヴァクシンズ アンド ダイアグノスティクス， インコーポレイテッド Substituted quinoline derivatives as mitotic kinesin inhibitors
JP4836280B2 (en) * 2004-06-18 2011-12-14 ノバルティス バクシンズ アンド ダイアグノスティックス，インコーポレーテッド N- (1- (1-benzyl-4-phenyl-1H-imidazol-2-yl) -2,2-dimethylpropyl) benzamide derivatives and related as kinesin spindle protein (KSP) inhibitors for the treatment of cancer Compound
EP1807399A2 (en) * 2004-10-19 2007-07-18 Novartis Vaccines and Diagnostics, Inc. Indole and benzimidazole derivatives
TW200800951A (en) * 2005-08-09 2008-01-01 Novartis Ag Substituted imidazole compounds as KSP inhibitors
US8129358B2 (en) * 2006-11-13 2012-03-06 Novartis Ag Substituted pyrazole and triazole compounds as KSP inhibitors

Also Published As

Publication number Publication date
AU2008205169A1 (en) 2008-07-17
EP2106399A2 (en) 2009-10-07
US20110003791A1 (en) 2011-01-06
CO6561828A2 (en) 2012-11-15
GT200900192A (en) 2010-06-24
UA97821C2 (en) 2012-03-26
MX2009007260A (en) 2009-07-10
PE20081850A1 (en) 2009-02-05
AU2008205169B2 (en) 2012-02-02
CL2008000029A1 (en) 2008-04-04
EA200900924A1 (en) 2009-12-30
CA2674318A1 (en) 2008-07-17
US20080207589A1 (en) 2008-08-28
CN101622247A (en) 2010-01-06
BRPI0806264A2 (en) 2011-08-30
ZA200904175B (en) 2010-04-28
WO2008086122A3 (en) 2008-10-16
MA31080B1 (en) 2010-01-04
SMAP200900065A (en) 2009-09-07
KR20090097210A (en) 2009-09-15
ECSP099485A (en) 2009-08-28
WO2008086122A2 (en) 2008-07-17
TN2009000287A1 (en) 2010-12-31
SV2009003325A (en) 2011-08-09
SMP200900065B (en) 2010-09-10
US20120189623A1 (en) 2012-07-26
NI200900134A (en) 2010-07-05
DOP2009000169A (en) 2009-08-31
GEP20125415B (en) 2012-03-12
TW200836722A (en) 2008-09-16
JP2010515687A (en) 2010-05-13
AR064760A1 (en) 2009-04-22
US7820646B2 (en) 2010-10-26
HN2009001262A (en) 2012-01-09
NZ577727A (en) 2012-03-30

Similar Documents

Publication Publication Date Title
DK2164844T3 (en) Pyrimidinyl-pyridazinone derivatives
DK2209786T3 (en) PYRIMIDINE-SUBSTITUTED PURINDER DERIVATIVES
DK2308877T3 (en) Imidazopyridine-2-one derivatives
ATE549340T1 (en) SPIROINDOLINONE DERIVATIVES AS MDM2-P53 INHIBITORS
BRPI0818457A2 (en) OXADIAZOL DERIVATIVES
EP2192838A4 (en) HETEROCYCLIC INHIBITORS OF NECROPTOSIS
DOP2007000084A (en) DERIVATIVES OF DIHYDROPIRAZOLOPIRIMIDINONE
BRPI0820112A2 (en) ISOXAZOL-PYRIDINE DERIVATIVES
BRPI0918846A2 (en) heterocyclic kinase inhibitors
BRPI0809992A2 (en) PYROLOPYRIMIDINE DERIVATIVES
BRPI0813836A2 (en) PYRAZOLIC DERIVATIVES
BRPI0820113A2 (en) ISOXAZOLE-PYRIDAZINE DERIVATIVES
EP2266989A4 (en) HETEROCYCLIC DERIVATIVES
SMAP200900065A (en) Cyclized derivatives as eg-5 inhibitors
ATE506358T1 (en) 2-BENZYLPYRIDAZINONE DERIVATIVES AS MET KINASE INHIBITORS
BRPI0817935A2 (en) BIARILLE DERIVATIVES
ATE533761T1 (en) IMIDAZOLIDINONE DERIVATIVES
BRPI0915064A2 (en) qunoxalinadione derivatives
ATE518837T1 (en) INDAZOLAMIDE DERIVATIVES
BRPI0814236A2 (en) QUINAZOLINAMIDE DERIVATIVES
BRPI0913832A2 (en) pyrrolopyridinylpyrimidin-2-ylamine derivatives
BRPI0820649A2 (en) Isoxazalo-pyrazine derivatives
DK2152370T3 (en) Aryletherpyridazinone derivatives
BRPI0811212A2 (en) P70 Kinase Inhibitors
DK2275414T3 (en) CYCLOPENTYLACRYLAMIDE DERIVATIVES